Objective To investigate the efficacy of sorafenib toluene sulfonate combined with transcatheter arterial che-moembolization(TACE)in patients with unresectable localized liver cancer.Methods Patients with unresectable localized liver cancer were selected as the research objects.They were randomly divided into the control group and the observation group.The ob-servation group was treated with sorafenib toluene sulfonate combined with TACE,and the control group was treated with TACE a-lone.The clinical efficacy,the level of tumor markers[alpha fetoprotein(AFP),carbohydrate antigen(CA19-9)],the level of liv-er function indicators[alanine aminotransferase(ALT),total bilirubin(TBIL),albumin(ALB)]and the incidence of adverse re-actions were compared between the 2 groups.Results The objective remission rate was 33.33%in the control group and 54.17%in the observation group,the difference was statistically significant(P<0.05).The disease control rate was62.50%in the control group and 87.50%in the observation group,the difference was statistically significant(P<0.05);The levels of AFP,CA19-9,ALT,Tbil and Alb in the control group were significantly lower than those in the control group(P<0.05).Adverse reac-tion of the 2 groups had no statistical difference(P<0.05).Conclusion Sorafenib tosylate combined with TACE has a better clinical effect in patients with unresectable localized liver cancer,with less damage to liver function and no increase in adverse re-actions,which is safer and more reliable.
维普
万方数据
